Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Veru (VERU.O), opens new tab said on Monday its experimental drug in combination with Novo Nordisk's (NOVOb.CO), opens new tab weight-loss treatment Wegovy, helped preserve muscle in older ...

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Veru is one biotech that thinks it’s found ... are already receiving Novo Nordisk’s blockbuster weight loss drug Wegovy. The drug, while heralded as a strong weight loss drug, has however ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

In a Phase 2b trial, older patients taking Novo Nordisk’s Wegovy and Veru’s experimental drug, called enobosarm, lost on average 1.2% of lean mass after 16 weeks, compared with a 4.1% loss in ...